Gupta A., Gupta V., Thapar S., Bhansali A.Lipid-lowering drug atorvastatin as an adjunct in the management of diabetic macular oedema. Am J Ophthalmol2004 ;137:675-82.
2.
Zander E., Herfurt S., Bohl B. et al. Maculopathy in patients with diabetes mellitus type 1 and type 2: associations with risk factors. Br J Ophthalmol2000;84:871-6.
3.
Cusick M., Chew EY, Chan CC, Kruth HS, Murphy RP, Ferris FL 3rd.Histopathology and regression of retinal hard exudates in diabetic retinopathy after reduction of elevated serum lipid levels. Ophthalmology2003;110:2126-33.
4.
Klein R., Klein BE, Moss SE, Davis MD, DeMets DLThe Wisconsin Epidemiologic Study of Diabetic Retinopathy. X. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is 30 years or more. Arch Ophthalmol1989;107:244-49.
5.
Chew EY, Klein ML, Ferris FL 3rd et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Arch Ophthalmol1996;114:1079-84.
6.
Mohan R., Mohan V., Susheela L., Ramachandran A., Viswanathan M.Increased LDL cholesterol in non-insulin-dependent diabetics with maculopathy . Acta Diabetol Lat1984;21:85-9.
7.
Chowdhury TA , Hopkins D., Dodson PM, Vafidis GCThe role of serum lipids in exudative diabetic maculopathy: is there a place for lipid lowering therapy?Eye2002;16:689-93.
8.
The FIELD study investigators.Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus: randomised controlled trial . Lancet2005;366:1849-61.
9.
Duncan LJ, Cullen JF, Ireland JT et al. A three-year trial of atromid therapy in exudative diabetic retinopathy. Diabetes1968;17:458-67.
10.
Harrold BP, Marmion VJ, Gough KRA double-blind controlled trial of the use of clofibrates in the treatment of Diabetic Retinopathy. Diabetes1969;18:285-91.
